Physician profile
Kevin K Dodd
NPI 1437130085
$12,874.72
in general payments reported to CMS, 2019-2025
38 companies · $2,055 in 2025
The $2,055 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,421 · 2020: $2,171 · 2021: $1,331 · 2022: $1,399 · 2023: $1,793 · 2024: $1,706 · 2025: $2,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,496 · Education: $58.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,495.61 |
| Education | $58.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,056.44 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Gilead Sciences, INC. | $1,765.41 | 2019-2025 | Epclusa, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,428.44 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $989.03 | 2019-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $868.23 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $769.99 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $632.89 | 2019-2025 | |
| Redhill Biopharma INC. | $500.29 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Intercept Pharmaceuticals, INC. | $346.72 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $342.62 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $246.34 | 2019-2024 | Linzess |
| Ardelyx, INC. | $245.36 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $178.05 | 2019-2023 | Sutab, Suflave |
| Celgene Corporation | $175.99 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $142.47 | 2019-2025 | Rebyota |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $141.32 | 2021-2022 | |
| Romark Laboratories, Lc | $112.50 | 2019-2020 | |
| Allergan, INC. | $102.98 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $97.20 | 2019 | |
| Celltrion USA INC. | $76.30 | 2024 | Zymfentra |
| Aimmune Therapeutics, INC. | $75.15 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $73.77 | 2025 | Iqirvo |
| Lilly USA, LLC | $51.70 | 2025 | Omvoh |
| Organon LLC | $46.92 | 2023 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $43.00 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.74 | 2023 | Cyltezo |
| Novo Nordisk INC | $39.53 | 2025 | Wegovy |
| Blueprint Medicines Corporation | $37.03 | 2023 | |
| Alfasigma USA, INC. | $35.52 | 2020 | |
| Ucb, INC. | $29.40 | 2019 | |
| Capsovision, INC. | $29.29 | 2024-2025 | Capsocam Plus |
| Conmed Corporation | $25.98 | 2019 | |
| Olympus America INC. | $24.87 | 2025 | Single Use Repositionable Clip |
| Orphalan INC | $23.32 | 2024 | Cuvrior |
| Genzyme Corporation | $23.00 | 2023 | |
| Madrigal Pharmaceuticals | $20.20 | 2025 | Rezdiffra |
| Biocon Biologics INC | $18.76 | 2025 | Yesintek |
| Concordia Pharmaceuticals INC. | $15.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.